Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Digestive Diseases and Sciences

• Publication date

  2018-01-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10620-017-4903-5PMID 29368124
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg

  2018cited by this paper
• Elastography methods for the non-invasive assessment of portal hypertension

  2018cited by this paper
• Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease

  2018cited by this paper
• Invasive and non-invasive assessment of portal hypertension

  2018cited by this paper
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

  2017cited by this paper
• Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

  2017cited by this paper
• Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients

  2017cited by this paper
• Novel treatment options for portal hypertension

  2017cited by this paper
• Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis

  2017cited by this paper
• Perspectives on NASH Histology: Cellular Ballooning.

  2017influential reference
• Targeting the gut-liver axis in liver disease.

  2017cited by this paper
• The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

  2017cited by this paper
• Correlation of transient elastography with hepatic venous pressure gradient in patients with cirrhotic portal hypertension: A study of 326 patients from India

  2017cited by this paper
• Liver sinusoidal endothelial cells: Physiology and role in liver diseases.

  2017influential reference
• Noninvasive assessment of portal hypertension and detection of esophageal varices in cirrhosis: state-of-the-art.

  2017cited by this paper
• Use of Statins in Patients with Chronic Liver Disease and Cirrhosis: Current Views and Prospects

  2017cited by this paper
• Magnetic Resonance Elastography Shear Wave Velocity Correlates with Liver Fibrosis and Hepatic Venous Pressure Gradient in Adults with Advanced Liver Disease

  2017cited by this paper
• Statin Use and Risk of Cirrhosis and Related Complications in Patients With Chronic Liver Diseases: A Systematic Review and Meta‐analysis

  2017cited by this paper
• The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

  2017cited by this paper
• Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity

  2017cited by this paper
• Mitochondria‐targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats

  2017cited by this paper
• Ultrasonography for Noninvasive Assessment of Portal Hypertension

  2017cited by this paper
• The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells

  2017cited by this paper
• Optimizing EUS-guided liver biopsy sampling: comprehensive assessment of needle types and tissue acquisition techniques.

  2017cited by this paper
• Microbiota-induced obesity requires farnesoid X receptor

  2016cited by this paper
• Emerging therapies for portal hypertension in cirrhosis

  2016cited by this paper
• Prediction of esophageal varices and variceal hemorrhage in patients with acute upper gastrointestinal bleeding

  2016cited by this paper
• Probe‐based confocal laser endomicroscopy quantitative morphometric markers associated with portal hypertension in duodenal mucosa

  2016cited by this paper
• Novel 3D Magnetic Resonance Elastography for the Noninvasive Diagnosis of Advanced Fibrosis in NAFLD: A Prospective Study

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis.

  2016cited by this paper
• Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study

  2016cited by this paper
• Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging

  2016cited by this paper
• Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension

  2016cited by this paper
• Liver stiffness in nonalcoholic fatty liver disease: A comparison of supersonic shear imaging, FibroScan, and ARFI with liver biopsy

  2016cited by this paper
• EUS-guided portal pressure measurement using a digital pressure wire with real-time remote display: a novel, minimally invasive technique for direct measurement in an animal model.

  2016cited by this paper
• Sinusoidal communication in liver fibrosis and regeneration.

  2016cited by this paper
• Nonalcoholic Fatty Liver Disease and the Gut Microbiome.

  2016cited by this paper
• Cerium oxide nanoparticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis.

  2016cited by this paper
• Transient Elastography (Fibroscan) in Patients with Non-cirrhotic Portal Fibrosis.

  2016cited by this paper
• Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.

  2016cited by this paper
• Natural History of Nonalcoholic Fatty Liver Disease

  2016cited by this paper
• EUS-guided portal pressure gradient measurement with a novel 25-gauge needle device versus standard transjugular approach: a comparison animal study.

  2016cited by this paper
• Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease

  2016cited by this paper
• Does pressure cause liver cirrhosis? The sinusoidal pressure hypothesis

  2016cited by this paper
• New Developments on the Treatment of Liver Fibrosis

  2016cited by this paper
• Expanding consensus in portal hypertension Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension

  2015cited by this paper
• Pivotal role of liver sinusoidal endothelial cells in NAFLD/NASH progression

  2015cited by this paper
• The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.

  2015cited by this paper
• Nonalcoholic fatty liver disease: portal hypertension due to outflow block in patients without cirrhosis.

  2015cited by this paper
• Metformin reduces hepatic resistance and portal pressure in cirrhotic rats.

  2015cited by this paper
• Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.

  2015cited by this paper
• Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension.

  2015cited by this paper
• Peripheral and Hepatic Vein Cytokine Levels in Correlation with Non-Alcoholic Fatty Liver Disease (NAFLD)-Related Metabolic, Histological, and Haemodynamic Features

  2015cited by this paper
• The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique

  2015cited by this paper
• Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease.

  2015cited by this paper
• Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study.

  2015cited by this paper
• Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability

  2015cited by this paper
• Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis

  2015cited by this paper
• Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

  2014cited by this paper
• Measurement of portal pressure.

  2014cited by this paper
• Non-cirrhotic portal hypertension--concept, diagnosis and clinical management.

  2014cited by this paper
• Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences.

  2014cited by this paper
• Hepatic venous pressure gradient: clinical use in chronic liver disease

  2014cited by this paper
• Mechanisms of Liver Injury in Non-Alcoholic Steatohepatitis

  2014cited by this paper
• Magnetic Resonance Elastography Predicts Advanced Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Study

  2014cited by this paper
• Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

  2014cited by this paper
• Invasive and non-invasive diagnosis of cirrhosis and portal hypertension.

  2014cited by this paper
• Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo

  2014cited by this paper
• Non-alcoholic steatohepatitis: a microbiota-driven disease.

  2013cited by this paper
• Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models

  2013cited by this paper
• Lipid-Induced Toxicity Stimulates Hepatocytes to Release Angiogenic Microparticles That Require Vanin-1 for Uptake by Endothelial Cells

  2013influential reference
• The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins.

  2013cited by this paper
• Terutroban, a TP‐receptor antagonist, reduces portal pressure in cirrhotic rats

  2013cited by this paper
• Celecoxib Ameliorates Portal Hypertension of the Cirrhotic Rats through the Dual Inhibitory Effects on the Intrahepatic Fibrosis and Angiogenesis

  2013cited by this paper
• Spleen Stiffness in Patients With Cirrhosis in Predicting Esophageal Varices

  2013cited by this paper
• Targeting the Gut–Liver Axis in Cirrhosis: Antibiotics and Non-Selective β-Blockers

  2013cited by this paper
• Bile Acid Receptor Activation Modulates Hepatic Monocyte Activity and Improves Nonalcoholic Fatty Liver Disease*

  2013cited by this paper
• The global NAFLD epidemic

  2013cited by this paper
• Chronic liver disease: noninvasive subharmonic aided pressure estimation of hepatic venous pressure gradient.

  2013influential reference
• PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.

  2012cited by this paper
• Adenoviral dominant-negative soluble PDGFRβ improves hepatic collagen, systemic hemodynamics, and portal pressure in fibrotic rats.

  2012cited by this paper
• Endo-hepatology: a new paradigm.

  2012cited by this paper
• Portal hypertension and liver cirrhosis in rats: effect of the β3‐adrenoceptor agonist SR58611A

  2012influential reference
• Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease.

  2012cited by this paper
• FXR ligands protect against hepatocellular inflammation via SOCS3 induction.

  2012cited by this paper
• Intestinal decontamination inhibits TLR4 dependent fibronectin-mediated cross-talk between stellate cells and endothelial cells in liver fibrosis in mice.

  2012cited by this paper
• Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD

  2012cited by this paper
• Von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis

  2012cited by this paper
• Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.

  2011cited by this paper
• Centrizonal Arteries and Microvessels in Nonalcoholic Steatohepatitis

  2011cited by this paper
• Increased production of sonic hedgehog by ballooned hepatocytes

  2011cited by this paper
• Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease

  2010cited by this paper
• Non‐alcoholic steatohepatitis induces non‐fibrosis‐related portal hypertension associated with splanchnic vasodilation and signs of a hyperdynamic circulation in vitro and in vivo in a rat model

  2010cited by this paper
• Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand

  2010cited by this paper
• Hepatocellular ballooning in NASH.

  2010cited by this paper
• Noncirrhotic human nonalcoholic fatty liver disease induces portal hypertension in relation to the histological degree of steatosis

  2010cited by this paper
• Role of β3‐adrenoceptors for intrahepatic resistance and portal hypertension in liver cirrhosis

  2009influential reference
• Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.

  2009cited by this paper
• Kupffer cells in non-alcoholic fatty liver disease: the emerging view.

  2009cited by this paper

• Visceral Versus Subcutaneous Adipose Tissue: Immune Microenvironment and Metabolic Consequences

  2026cites this paper
• NAFLD accelerates arterial perfusion in rabbit VX2 liver tumors: a sonoVue-based contrast-enhanced ultrasound study

  2025cites this paper
• Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment

  2025cites this paper
• Assessment and management of portal hypertension in patients with MASLD: advances and caveats

  2025cites this paper
• Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review

  2025cites this paper
• Advances in Endo-Hepatology: The Role of Endoscopic Ultrasound in the Management of Portal Hypertension

  2025cites this paper
• Detecting Portal Venous Blood Flow in Metabolic Dysfunction-Associated Fatty Liver Disease Using Non-Invasive Doppler Ultrasound

  2025cites this paper
• The Interplay between Liver Sinusoidal Endothelial Cells, Platelets, and Neutrophil Extracellular Traps in the Development and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2024cites this paper
• Endo-hepatology: Why should we do endoscopic ultrasound-guided interventions to the liver that we could do through the skin?

  2024cites this paper
• Hepatic microcirculatory disturbance in liver diseases: intervention with traditional Chinese medicine

  2024influential citation
• Gut Microbiota and Sinusoidal Vasoregulation in MASLD: A Portal Perspective

  2024cites this paper
• Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression

  2024cites this paper
• Portal Hypertension in Nonalcoholic Fatty Liver Disease: Challenges and Paradigms

  2023cites this paper
• Metabolic dysfunction-associated steatotic liver disease and the heart

  2023cites this paper
• Portal Venous Pulsatility Index Pak Armed Forces Med J 2023; 73(4): 1091 Portal Venous Pulsatility Index: A Novel Biomarker for Diagnosis of High-Risk Non- Alcoholic Fatty Liver Disease

  2023influential citation
• Portal hypertension in NASH : is it different from other aetiologies?

  2023cites this paper
• Morbid Obesity Associated with Non-Alcoholic Fatty Liver Disease and Complicated by Severe Non-Cirrhotic Portal Hypertension: A Case Report from Rural Kenya

  2023cites this paper
• Mechanobiology of portal hypertension

  2023cites this paper
• Targeting Endothelial Necroptosis Disrupts Profibrotic Endothelial–Hepatic Stellate Cells Crosstalk to Alleviate Liver Fibrosis in Nonalcoholic Steatohepatitis

  2023cites this paper
• Endoscopic ultrasound-guided portal pressure gradient measurement in managing portal hypertension

  2023cites this paper
• Curcumin Alleviates High-fat Diet-induced Nonalcoholic Steatohepatitis via Improving Hepatic Endothelial Function with Microbial Biotransformation in Rats.

  2023cites this paper
• Fatty liver disease, heart rate and cardiac remodelling: Evidence from the UK Biobank

  2023cites this paper
• Evaluasi Shear Wave Elastography, Fibroscan dan Kecepatan Aliran Vena Porta pada Pasien Non-Alcoholic Fatty Liver Disease

  2022cites this paper
• Metabolic-associated fatty liver disease: from simple steatosis towards liver cirrhosis and potential complications. Proceedings of the Third Translational Hepatology Meeting, endorsed by the Spanish Association for the Study of the Liver (AEEH)

  2022cites this paper
• Microbiota transplantation in portal hypertension: promises and pitfalls.

  2022cites this paper
• Changes in Histological Structure, Interleukin 12, Smooth Muscle Actin and Nitric Oxide Synthase 1. and 3. Expression in the Liver of Running and Non-Running Wistar Rats Supplemented with Bee Pollen or Whey Protein

  2022cites this paper
• Influence of Gut–Liver Axis on Portal Hypertension in Advanced Chronic Liver Disease: The Gut Microbiome as a New Protagonist in Therapeutic Management

  2022cites this paper
• Mechanotransduction in the pathogenesis of nonalcoholic fatty liver disease.

  2022cites this paper
• Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications

  2022cites this paper
• Role of Angiogenesis in the Pathogenesis of NAFLD

  2021cites this paper
• Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early NAFLD

  2021influential citation
• A new perspective on NAFLD: focusing on lipid droplets.

  2021cites this paper
• Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach

  2021cites this paper
• Decreased portal circulation augments fibrosis and ductular reaction in nonalcoholic fatty liver disease in mice.

  2021cites this paper
• Idiopathic Non-Cirrhotic Portal Hypertension and Porto-Sinusoidal Vascular Disease: Review of Current Data

  2021cites this paper
• Severe Protein-Calorie Malnutrition-Associated Hepatic Steatosis in a Woman Who Had Roux-en-Y Gastric Bypass for Morbid Obesity Thirteen Years Ago

  2021cites this paper
• Targeting Liver Sinusoidal Endothelial Cells: An Attractive Therapeutic Strategy to Control Inflammation in Nonalcoholic Fatty Liver Disease

  2021cites this paper
• Matrix stiffness and shear stresses modulate hepatocyte functions in a fibrotic liver sinusoidal model.

  2020cites this paper
• Translational insight into prothrombotic state and hypercoagulation in nonalcoholic fatty liver disease.

  2020cites this paper
• Non-Alcoholic Fatty Liver Disease: A 360-degree Overview

  2020cites this paper
• Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model

  2020cites this paper
• Nonalcoholic fatty liver disease and portal hypertension.

  2020influential citation
• Short-Term Western Diet Aggravates Non-Alcoholic Fatty Liver Disease (NAFLD) With Portal Hypertension in TGR(mREN2)27 Rats

  2020cites this paper
• Emerging Roles of Liver Sinusoidal Endothelial Cells in Nonalcoholic Steatohepatitis

  2020cites this paper
• NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications

  2020cites this paper
• Portal Hypertension in NASH: Is It Different from Other Aetiologies?

  2019cites this paper
• Molecular and ultrastructure study of endoplasmic reticulum stress in hepatic steatosis: role of hepatocyte nuclear factor 4α and inflammatory mediators

  2019cites this paper
• Discovery of Gut Bacteria Specific to Alzheimer’s Associated Diseases is a Clue to Understanding Disease Etiology: Meta-Analysis of Population-Based Data on Human Gut Metagenomics and Metabolomics

  2019cites this paper
• Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease.

  2019cites this paper
• Generic chemoprevention of hepatocellular carcinoma

  2018cites this paper
• cGMP-dependent protein kinase I (cGKI) modulates human hepatic stellate cell activation.

  2018cites this paper
• Non-parenchymal hepatic cell lipotoxicity and the coordinated progression of non-alcoholic fatty liver disease and atherosclerosis

  2018cites this paper
• Potential mechanisms linking gut microbiota and portal hypertension

  2018cites this paper
• Invasive and non-invasive assessment of portal hypertension

  2018cites this paper
• World Journal of Gastroenterology

  year unknowncites this paper